Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms

Oncotarget - Tập 9 Số 24 - Trang 16932-16950 - 2018
Richard P. Baum1, Harshad Kulkarni1, Aviral Singh1, Daniel Kaemmerer2, Dirk Müeller1, Vikas Prasad3, Merten Hommann2, F Robiller4, Karin Niepsch1, Holger Franz5, Arthur Jochems6, Philippe Lambin7,6, Dieter Hörsch8
1THERANOSTICS Center for Molecular Radiotherapy, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
2Department of General and Visceral Surgery, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
3Clinic for Nuclear Medicine, Charité, Berlin, Germany
4Center of Molecular Imaging, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
5Lohmann and Birkner, Berlin, Germany
6Department of Radiology, GROW - School for Oncology and Developmental Biology, Maastricht University Hospital, Maastricht, The Netherlands
7Department of Radiation Oncology (The D-Lab), GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
8Department of Gastroenterology/Endocrinology, Center for Neuroendocrine Tumors Bad Berka - ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Bad Berka, Germany

Tóm tắt

Từ khóa


Tài liệu tham khảo

Delle Fave, 2016, Digestive neuroendocrine neoplasms: A 2016 overview, Dig Liver Dis, 48, 829, 10.1016/j.dld.2016.04.008

Inzani, 2014, The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction, Endocr Pathol, 25, 186, 10.1007/s12022-014-9313-z

Klöppel, 2017, Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications, Visc Med, 33, 324, 10.1159/000481390

Modlin, 2016, A short history of neuroendocrine tumours and their peptide hormones, Best Pract Res Clin Endocrinol Metab, 30, 3, 10.1016/j.beem.2015.10.004

Krug, 2016, Neuroendocrine tumours - Medical therapy: Biological, Best Pract Res Clin Endocrinol Metab, 30, 79, 10.1016/j.beem.2015.09.004

Arnold, 2017, Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival, Neuroendocrinology, 104, 26, 10.1159/000443612

Martinez, 2016, Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study, Endocr Relat Cancer, 23, 191, 10.1530/ERC-15-0490

Delbeke, 2016, Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors, J Nucl Med, 57, 708, 10.2967/jnumed.115.163865

Krenning, 2016, Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer, Semin Nucl Med, 46, 225, 10.1053/j.semnuclmed.2015.12.003

Kwekkeboom, 2016, PRRT of neuroendocrine tumours, Best Pract Res Clin Endocrinol Metab, 30, 103

Baum, 2016, Effectiveness and side-effects of PRRT for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up, Eur J Cancer, 58, 41, 10.1016/j.ejca.2016.01.009

Baum, 2017, Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors, N Engl J Med, 376, 125, 10.1056/NEJMoa1607427

Hacker, 2010, 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors, J Nucl Med, 51, 1349, 10.2967/jnumed.110.075002

Reichmann, 2012, Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?, Clin Nucl Med, 37, e141, 10.1097/RLU.0b013e31823926e5

Baum, 2012, Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing PRRT, Eur J Nucl Med Mol Imaging, 39, 501, 10.1007/s00259-011-2003-x

Giesel, 2015, SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors, Mol Imaging Biol, 17, 313, 10.1007/s11307-014-0795-3

van Echteld, 2017, [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study, Theranostics, 13, 501

Beyer, 2016, Does receptor status impact survival of patients with mid-gut neuroendocrine tumors, J Clin Oncol, 34, 227, 10.1200/jco.2016.34.4_suppl.227

Walter, 2012, Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers, J Clin Oncol, 30, 1100, 10.1200/JCO.2011.37.2151

Turner, 2015, NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study, Cancer Biother Radiopharm, 30, 261, 10.1089/cbr.2015.1876

Turner, 2016, Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy, Neuroendocrinology, 103, 32

Öberg, 2016, Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study, J Clin Oncol, 34, 3906, 10.1200/JCO.2016.68.0702

Turoglu, 2016, Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors, Nucl Med Commun, 37, 9, 10.1097/MNM.0000000000000401

Walter, 2011, Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers, J Clin Oncol, 29, 2416, 10.1200/JCO.2010.33.7873

Turner, 2016, Myelotoxicity of PRRT of Neuroendocrine Tumors: A Decade of Experience, Cancer Biother Radiopharm, 31, 189, 10.1089/cbr.2016.2035

Chiti, 2016, Myeloid neoplasms after chemotherapy and PRRT: myth and reality, Endocr Relat Cancer, 23, C1, 10.1530/ERC-16-0258

Ezziddin, 2013, Long-term hematotoxicity after PRRT with 177Lu-octreotate, J Nucl Med, 54, 1857, 10.2967/jnumed.112.119347

Kwekkeboom, 2016, Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate, Eur J Nucl Med Mol Imaging, 43, 1802, 10.1007/s00259-016-3382-9

Kwekkeboom, 2013, The joint IAEA, EANM, and SNMMI practical guidance on PRRT (PRRNT) in neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 40, 800, 10.1007/s00259-012-2330-6

Breeman, 2012, Simplified NaCl based (68)Ga concentration and labeling procedure for rapid synthesis of (68)Ga radiopharmaceuticals in high radiochemical purity, Bioconjug Chem, 23, 1712, 10.1021/bc300103t

Schultz, 2016, Radiolabeling of DOTA-like conjugated peptides with generator-produced Ga-68 and using NaCl-based cationic elution method, Nat Protoc, 11, 1057, 10.1038/nprot.2016.060

Baum, 2007, Results of individual patient dosimetry in PRRT with 177Lu DOTA-TATE and 177Lu DOTA-NOC, Cancer Biother Radiopharm, 22, 406, 10.1089/cbr.2006.325

Baum, 2013, PRRT with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient, Recent Results Cancer Res, 194, 551, 10.1007/978-3-642-27994-2_32

Baum, The Bad Berka dose protocol: comparative results of dosimetry in PRRT using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC, Recent Results Cancer Res, 2013, 519

Carreras, 2012, Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms, Semin Nucl Med, 42, 190, 10.1053/j.semnuclmed.2012.01.002

R Core Team. R: A language and environment for statistical computing. R foundation for Statistical Computing, Vienna, Austria. 2012. Available online at http://www.R-project.org/.

Heiberger, 1992, In Statistical Models Eds JM Chambers & TJ Hastie

Cox, 1972, Regression models and life tables (with discussion), Journal of the Royal Statistical Society, Series B, 34, 187, 10.1111/j.2517-6161.1972.tb00899.x

Price, 1999, Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4